REVO looks to expand use of Atryn with preeclampsia PhIII

Framingham, MA-based rEVO Biologics--formerly GTC Biotherapeutics--is planning to put its drug ATryn through a late-stage study for preeclampsia, looking to see if it can help women extend their pregnancy, helping the women as well as their newborns. The drug was initially approved back in 2009 and is made from the milk of genetically engineered goats. Release